Introduction: Seasonal influenza vaccination is recommended for all individuals aged 65 years and over and in individuals younger than 65 years with comorbidities. There is good evidence of vaccine effectiveness (VE) in young healthy individuals but less robust evidence for effectiveness in the populations targeted for influenza vaccination. Undertaking a randomised controlled trial to assess VE is now impractical due to the presence of national vaccination programmes. Quasi-experimental designs offer the potential to advance the evidence base in such scenarios, and the authors have therefore been commissioned to undertake a naturalistic national evaluation of seasonal influenza VE by using data derived from linkage of a number of Scottish health databases. The aim of this study is to examine the effectiveness of the seasonal influenza vaccination in the Scottish population.
INTRODUCTION
Each year, influenza causes substantial morbidity and mortality, particularly in people aged 65 years and over and those with underlying serious comorbidities. In the USA, it has been estimated that influenza is responsible for 186 000 excess hospitalisations and 44 000 excess deaths. 1 National vaccination strategies represent a potentially important approach to reduce both influenza-related illness and death, hence the considerable investment in this approach in many parts of the world. Although Strengths and limitations of this study -The study population comprises a large unbiased sample of the general population. - We are developing a unique linked national database, which contains anonymised individual patient-level data from general practices, hospitals, virology investigations and the death register. -Our analysis plan takes a robust and comprehensive approach to the well-described problem of confounding in VE studies. -As this is an observational study, residual confounding may still be present despite the comprehensive approach we plan to take to deal with this.
vaccination rates in those over 65 in Scotland are a reasonable 75.0% (season 2009/2010), the rates in atrisk groups younger than 65 years remain low (53.4% in season 2009/2010) despite widely promulgated guidelines and incentivised vaccination programmes. 2 There is good evidence of the benefits of the vaccine in young healthy adults and children, 3 but a scarcity of reliable estimates from randomised controlled trials in at-risk populations. 4 There is also limited evidence from observational research, which has only shown effectiveness of vaccination in selected groups of patients, for example, those aged over 65 years 5 or those in at-risk groups for single influenza seasons. 6 Furthermore, these studies may have been prone to bias and residual confounding. 4 7 This may explain, in part, the reason for lower vaccine uptake rates. Randomised controlled trials offer the best opportunity to produce unbiased estimates of vaccine effectiveness (VE). However, given that influenza vaccination programmes exist in most developed countries, this form of study design is now impractical and is viewed by many in the medical community as unethical. 8 Observational studies are an alternative to investigate VE. However, an individual's decision to attend the local general practice surgery for vaccination may be a marker of healthier behaviour generally, as well as identifying more highly educated individuals who are more aware of and more likely to act on recommendations for their own health. These individuals may be less likely to die from any cause or be admitted to hospital, thus inducing a spurious relationship between vaccination status and the outcome (ie, positive confounding). Similarly, patients who are very frail and unable to attend the general practice surgery may be less likely to be vaccinated, but much more likely to die or be admitted to hospital. 9 This phenomenon is also known as the 'healthy vaccine effect'.
Standard methods of adjustment for confounders are likely to be inadequate to control for confounding due to the healthy vaccine effect. This can result in excessive estimates of VE in observational studies using non-influenza-specific outcomes due to residual confounding. A number of methods can be used to try and address this problem, including quasi-experimental study designs and advanced statistical methods. In addition, an analysis framework has been proposed to identify residual confounding when undertaking VE studies using observational methods. 10 This research aims to examine the effectiveness of the seasonal influenza vaccine while addressing the methodological challenges outlined above of using observational data. We will have access to a unique set of linked databases, which contain individual patient-level data relating to primary healthcare, acute hospital care, virological laboratory tests and mortality. In contrast to previous observational studies, these rich data sources provide information on a large number of potential confounders and highly specific laboratory outcome measures in a study cohort sampled from the general population. Our assessment of the effectiveness and impact of the seasonal influenza vaccination programme therefore offers potentially large societal benefits both for Scotland, the UK, and for advancing the international evidence base.
AIMS AND OBJECTIVES
We aim to examine the effectiveness of the seasonal influenza vaccination in individuals registered with a national sample of general practices in Scotland. More specifically, the objectives of this study are to (1) report vaccine uptake in the relevant at-risk populations for whom vaccination is recommended in the UK; (2) evaluate VE measured in terms of the following outcomes: rate of hospital admissions due to respiratory illness (primary outcome), rate of primary care consultations due to respiratory illness, risk of death due to respiratory illness and risk of laboratory-confirmed influenza infection and (3) assess the degree of and adjust for residual confounding in our estimates using analyses incorporating propensity scores, instrumental variables and the effect of a hypothetical unknown confounder.
METHODS

Study design and population
A cohort study design will be used to assess VE. Vaccine uptake will be reported using serial cross-sectional surveys. Data extracted from 35 general practices of the sentinel surveillance network in Scotland, the Practice Team Information network, will be used. Participating practices cover a 4% sample of the Scottish population (n¼209 452 registered alive in 2009). The population targeted for influenza vaccination comprises all patients aged 65 years and older (approximately 15% of the general population, n¼28 241 in the sample) and those aged younger than 65 years defined as being in an at-risk group on the basis of pre-existing illness (n¼w33 000, 18% of younger than 65-year-olds). 11 The estimates for proportion of patients younger than 65 years in an at-risk group were taken from our recent VIPER study investigating the effectiveness of the 2009 H1N1 pandemic influenza vaccine. 12 Each patient will contribute persontime to each influenza season while alive and registered with a participating general practice. The primary care database was linked to the Scottish acute hospital discharge database and Scottish death register as part of the VIPER project. 12 In addition, a linkage of these data sets to the Health Protection Scotland virology database to determine laboratory-confirmed influenza infection is underway (due to be completed on 1 February 2012).
Databases
Acute hospital discharge database The Information Services Division, National Services Scotland, maintains a database of all acute hospital discharges in Scotland, known as the Scottish Morbidity Record 1. All inpatient and day case episodes of care for acute hospitals since 1981 have been recorded in the database. The database is subject to regular validation checks, and the most recent quality assurance report indicated good levels of accuracy (>90%) for the fields used in this study. 13 Diagnostic information is recorded using International Classification of Disease version 10 (ICD-10). There are up to six fields that can be used to record diagnoses, with one allocated as the main reason for admission. Scottish Morbidity Record 1 is linked routinely by Information Services Division to the Scottish death register using patient characteristics in a probabilistic matching algorithm with a high degree of accuracy. 14 15 Primary care database Almost all individuals resident in Scotland are registered with a primary care practice, which provides healthcare services free of charge. Virtually all specialist hospital care services are also free of charge, usually obtained through referral from primary care or, in emergency situations, through patients attending an emergency department. Primary care-based physicians provide or coordinate much of the care of patients discharged back into the community by secondary and tertiary care services. The primary care database was linked to the other databases using probabilistic linkage. Linkage accuracy was high due to the high quality and number of patient identifiers available from the primary care database. Completeness of capture of contacts and accuracy of clinical event coding (using Read codes) has been found to be above 91% among the study practices. 16 17 The electronic recording of long-term prescribing information by primary care has also been found to be both accurate and complete. 18 
Death register
Details from death certificates issued for all deaths in Scotland are recorded in the death register, maintained by National Records Scotland. 19 Cause of death has been routinely coded using ICD-10 since 2000.
Health Protection Scotland virology database
The Scotland-wide unique patient identifier, the Community Health Index number, is being used to link records in the virology database to the other databases. There may be fewer virology records with adequate patient identifiable information to allow linkage for the years 2000e2005 of the study period. This is actively being investigated by coinvestigators.
Study period
Data from 1 September 2000 to 31 August 2009 will be used. This will allow analysis of nine influenza seasons (2000/2001 to 2008/2009). Each year (1 September to 31 August) will be divided into four periods (figure 1). The influenza season will be defined for each year using national influenza surveillance data. 20 The start of the period will be from the date of the first influenza isolate reported by Health Protection Scotland each year. The end of the influenza season will be the date of the last influenza isolate with an additional 14-day period for complications. The pre-influenza period will be defined as starting from 1 September each year until the date of the first influenza isolate. The post-influenza period will start 14 days after the last influenza isolate and end on 31 May each year. The 'non-influenza' period for each year will be from 1 June to 31 August (figure 1).
Exposure definition
Vaccination will be used to define exposure status if it is given at a time point between the start of the pre-influenza season (1 September) and the end of the influenza season ( figure 1 ). An individual will be defined as vaccinated 14 days after the seasonal influenza vaccine has been administered. 21 The time period from the first day of the influenza season to day 14 post-vaccination will be defined as 'unexposed' and the period from day 14 post-vaccination until the end of the influenza season will be defined as 'exposed'. Therefore, those vaccinated between the start of the pre-influenza period up until 14 days before the influenza season will be defined as 'exposed' for the duration of the influenza season.
Outcomes VE should ideally be measured using influenza-specific outcomes in each of the databases. However, it is likely that ICD codes or Read codes referring to influenzaspecific outcomes are underused by clinicians and coders, thereby reducing the sensitivity and power of the primary analysis. For this reason, codes for acute respiratory diseases were chosen as primary outcome measures as they would capture a substantial proportion of Additional sensitivity analyses will be undertaken using less-specific outcomes (all-cause mortality, emergency admission to hospital for any reason) as well as the influenza-specific outcomes (deaths due to influenza, hospital admissions due to influenza). These analyses will be part of the framework to assess bias (see below).
A number of secondary analyses will be undertaken using other outcomes. The effect of vaccination status on hospital admissions and deaths relating to cardiovascular and cerebrovascular events as a composite outcome will be analysed. In addition, exploratory analyses will be undertaken to assess the effect of vaccination status on outcomes for which it would not be expected to have an effect, for example, appendicitis or trauma. This approach of using an alternative outcome as a negative control has been shown to be a useful method for detecting residual bias. 22 Confounding factors Individuals who are vaccinated are likely to be different from those who are unvaccinated. An extensive list of individual-level and practice-level characteristics will be included as confounders in the analyses. These will be defined in each year on the first day of the pre-influenza season (1 September). Practice effects will be accounted for using multilevel methods.
Demographics
Sex, age-band (0e4, 5e14, 15e44, 45e64, 65e74 and 75+) and socioeconomic status will be included in all analyses; socioeconomic status will be measured using quintiles of the Scottish Index of Multiple Deprivation: 1¼most affluent and 5¼most deprived). Scottish Index of Multiple Deprivation is an area-based measure of deprivation derived from seven domains including income, employment and education. 23 At-risk groups At-risk patients are those with certain comorbidites for whom seasonal influenza vaccination is indicated.
Patients will be defined as high risk according to national guidance 11 if they have one or more of the following conditions: < chronic heart disease, < chronic kidney disease (including renal transplantation), < chronic liver disease, < chronic neurological disease, < chronic respiratory disease, < conditions or drugs causing impaired immune function and < diabetes.
Chronic diseases
Comorbidity will be defined by the 17 disease categories that constitute the Charlson Comorbidity Index. 24 This index has been validated in a number of different databases using codes from healthcare databases. 25 A recent study has mapped Read codes from a UK general practice database to the relevant Charlson comorbid disease groups, resulting in a model that performed well in the prediction of 5-year mortality. 26 These codes will be used to identify comorbidities that are present in a patent's record prior to the start of each pre-influenza season (1 September). The number of repeat prescription items issued in the previous 12-month period will be used as an additional measure of comorbidity. Measures of previous healthcare resource use will also capture other aspects of chronic health status.
Smoking status
This will be derived from primary care data (current smoker, ex-smoker, non-smoker) and determined on 1 September each year.
Previous vaccinations
A variable will be included for patients who have received seasonal influenza vaccination in the previous season to account for the possibility of persisting VE in the subsequent year. 27 Adjustment for previous pneumococcal vaccination at any time in the primary care record prior to 1 September each year will also be undertaken, which will be particularly important for less-specific outcome measures such as all-cause death.
Previous healthcare utilisation
The number of general practice consultations in the previous 12 months will be used as a measure of healthcare utilisation. Number of emergency admissions to hospital for any cause during the previous 12 months will be used as a marker of severity of chronic health status.
Functional status
There is no direct measure of functional status made in any of these national databases. However, individuals who require a home visit when consulting a general practitioner rather than attending the practice will be identified. This will be used as a proxy marker for poor mobility or frailty. In addition, individuals who are resident in some form of institutional care setting may be identifiable from the primary care database. This will also be used as an indicator of more severe functional limitation.
Laboratory methods
Not all patients receiving vaccination will have been swabbed for influenza. The majority of Practice Team Information general practices are involved in the Health Protection Scotland sentinel swabbing scheme, whereby practices are encouraged to submit five swab samples per week to the West of Scotland Specialist Virology Centre (for multiplex polymerase chain reaction testing for a range of respiratory pathogens) on any patient presenting for consultation in the practice for influenzalike illness and acute respiratory infections across all ages. Crucially, this is independent of whether the individual has or has not been vaccinated.
Subgroups for stratified analyses
The primary analysis will be performed using the whole cohort. A stratified analysis will be undertaken for those aged 65 years and older and those aged younger than 65 years old and by risk groups. This will allow VE to be assessed in more homogeneous subgroups and to check for effect modification across strata. Further subgroup analysis will be performed by restricting the study cohort to the main population group for whom the national influenza vaccination programme is targeted: those aged 65 years or older together with those aged younger than 65 years in an at-risk group. 11 It is likely that these analyses in subgroups will be underpowered, in particular in the younger than 65-year age group for whom event rates will be lower. Further stratified analyses will be undertaken as part of the framework to assess residual confounding (see section below).
Methods to further adjust for confounding
We plan to take a comprehensive approach to dealing with confounding due to the healthy vaccine effect in our study. This will include the use of complex statistical methods including propensity score analysis, instrumental variable analysis and modelling a hypothetical unmeasured confounder. These are considered in more detail below.
Propensity scores
Propensity scores are a well-described method to reduce the effect of strong confounding, such as confounding by indication. 28 We will develop a propensity score to predict the likelihood that a patient receives the seasonal influenza flu vaccine. This will allow for a better comparison to be made between vaccinated and unvaccinated groups. A logistic regression model will be constructed with vaccination status as the outcome in order to produce a score of the propensity to be vaccinated. The covariates in the model will be derived from available patient-and practice-level characteristics, which we consider to be clinically relevant to the probability of receiving the vaccination.
Instrumental variables
Instrumental variable analyses are well established in non-healthcare settings such as econometrics as a means of adjusting for unmeasured confounding. 29 An instrumental variable is a factor related to exposure status (ie, vaccination status), which does not have an independent effect on outcome other than by ways mediated through the exposure. Furthermore, an instrumental variable should not be related to any variables that confound the relationship between exposure and outcome. There are no instrumental variables that have been established as appropriate for analyses of VE. 30 For this reason, we will explore a number of variables that may fulfil the above criteria on a conceptual level.
Sensitivity analysis for unmeasured confounding
We will carry out a sensitivity analysis on the results of our primary analysis to explore the impact of an unmeasured confounding factor on the estimate of VE. 31 This will allow us to account for confounders such as poor functional status which is, as noted above, incompletely recorded in the national databases. This method assumes that the unmeasured confounder is not associated with the measured confounders in the model and is therefore likely to overestimate the impact of the unmeasured confounder. 32 Framework for detecting residual confounding As described earlier, we will undertake additional analyses to identify the presence of residual confounding. This has been recommended as part of an analytical framework when reporting VE using observational study designs. 33 We will assess the variation in VE using the following criteria: 1. Seasonality: stratification on season is more important when VE is measured using non-specific outcomes.
Each year of observation will be partitioned into four periods: non-influenza period, pre-influenza season, influenza season (when influenza virus is circulating) and post-influenza season ( figure 1 ). Maximal VE should be seen during the influenza season. The vaccine should have no effect on outcome in the pre-influenza and non-influenza seasons. The noninfluenza season will use vaccination status from the previous influenza season. This is to minimise the bias that might occur when vaccination status is applied retrospectively. This retrospective application of vaccine status would include patients who die during the preceding non-influenza season as unvaccinated, despite the fact that they would not have survived long enough to be eligible for vaccination.
Vaccine match: VE should be lower in years during
which the influenza vaccine was a poor match for the circulating virus. 3. Severity of influenza season: VE should be greater in years during which the circulating virus caused a large excess mortality during the influenza season. 4. Age: it is thought that influenza vaccine is less effective in the oldest age groups due to immune senescence. 33 If this assumption is correct, VE should be lowest in the oldest subgroup. A stratified analysis on age groups will be undertaken to assess for this effect. 5. Specificity of outcome measure: VE should be greatest for the most specific outcome (laboratoryconfirmed influenza infection) and lowest for the less-specific outcomes (all-cause mortality). In addition to the primary analysis, in the three nonlaboratory databases, we will undertake analyses using the more influenza-specific outcomes (influenza-coded deaths, hospital admissions and primary care attendances) and less-specific outcomes (allcause deaths, any emergency hospital admissions and any primary care attendances).
Statistical analysis
Baseline characteristics will be summarised by vaccination status for the whole cohort using mean, median or proportion where appropriate together with a measure of dispersion. Missing data will be reported for each variable. A 5% significance level will be used for hypothesis tests for the primary outcome. All p values will be two sided. All analyses will be undertaken in R. CIs for the RR and tests of the differences between two rates will be carried out using the 'midp method' in the RR function and rate2by2.test function, respectively, using the 'epitools' package in R. 34 For small samples, CIs for the RR will be estimated using the Excel workbook. Effect modification will be assessed across age groups, year and season by entering an interaction term into models. A complete case analysis will be the primary analysis. Multiple imputation using chained equations will be used, if necessary, to perform analyses on imputed data sets to assess the effect of missing data on VE estimates. 35 Annual and pooled analyses We will initially analyse each of the nine influenza seasons from 2000/2001 to 2008/2009 separately to calculate the VE for each season. We plan to test the homogeneity of the vaccine effect over the seasons, and if appropriate, pool the data to give a more powerful analysis than would be obtained using a simple aggregation of data. In the pooled analysis, we will account for the within-person correlation resulting from repeated measures on the same individual in subsequent seasons by the use of generalised estimation equations or an adjustment for clustering. This is likely to be more computationally efficient than hierarchical models. For the pooled analysis, we will be able to incorporate the effects of time and also to let the vaccine effect vary with year yet keeping the effect of the explanatory variables constant over time. If a pooled analysis is not considered appropriate, for example, if there is evidence of substantial heterogeneity in the VE over seasons, then we will use meta-regression models to try to explain this heterogeneity.
Vaccine uptake ORs (adjusted for age, sex and deprivation) will be calculated for differences in vaccine uptake rates between different groups of patients (sex, age, deprivation quintiles and at-risk groups).
Vaccine effectiveness
Crude and adjusted VE estimates will be reported for each outcome. VE estimates will be calculated for the cohort as a whole and stratified using the subgroups specified above. We will use the VE outcomes above to calculate numbers needed to vaccinate to prevent one swab-determined influenza infection, hospitalisation, consultation and death. A person-time denominator will be used for general practice consultations, hospital admissions and death. Follow-up time will be censored at death from any cause for consultations and admissions. Hospital admissions and consultations can have multiple events and each event will be counted.
Hospitalisations and primary care consultations
The ratio of the number of admissions to hospital per person-time during the post-vaccination period compared with the number of admission to hospital per person-time during the pre-vaccination period will be calculated. The unadjusted estimate of VE will be calculated as (1ÀRR)3100%. Adjusted RRs of VE for prevention of hospitalisation will be derived from Poisson regression models, adjusting for the confounders listed above. Similar methods will be used to estimate VE for primary care consultations.
Deaths
The OR of deaths in the vaccinated group to deaths in the unvaccinated group will be calculated; these will be both unadjusted and adjusted for the confounders listed above. VE will be calculated as (1ÀOR)3100%.
Laboratory-confirmed infection
For VE, using information from linked virological swab data, a logistic regression model will be fitted adjusting for the confounders listed above. VE will be measured by comparing swabs taken after vaccination with swabs taken before vaccination for all vaccinated individuals and second by comparing swabs taken after vaccination among those vaccinated to swabs taken among those never vaccinated. VE will be calculated as (1ÀOR)3100.
Statistical methods to further adjust for confounding Propensity score We will undertake analyses incorporating propensity scores using three different methods: regression (including propensity score as a covariate), stratification (based on quintile of propensity score) and matching (vaccinated and non-vaccinated patients individually matched by propensity score). The model will be non-parsimonious in order to include a wide range of factors that influence propensity to be vaccinated. The following covariates will be included in the model: age, sex, socioeconomic status, comorbidities for which vaccination is indicated (see above), comorbidities included in the Charlson Index, smoking status, previous vaccinations, functional status/frailty, number of primary care consultations in previous year, number of hospitalisations in previous year, number of repeat prescription items in previous year, practice type, overall practice deprivation, practice vaccination rate and influenza season.
Instrumental variable analysis
We will consider the following variables as potential instrumental variables: previous antacid prescription, previous thyroxine prescription, gout and screening attendance. We will assess whether these variables fulfil the following criteria for use as an instrumental variable: association with vaccination status (exposure), no association with outcome other than thorough exposure and no association with confounding variables. The rationale for selecting these variables is that each may increase the likelihood of a patient being opportunistically vaccinated while attending the general practitioner but should not be related to the risk of contracting influenza. If a suitable instrumental variable is found, analyses will be undertaken to produce VE estimates adjusted for the measured confounders and the instrumental variable. We will use a two-stage estimation method with logistic models used to combine the two equations.
Modelling an unmeasured confounder Death rates and hospital admission rates are likely to be highest in the frailest members of the study population. As these patients are less likely to seek vaccination, it has been suggested that inadequately measured frailty may explain some of the VE measured in observational studies. 7 9 As we may have been unable to fully account for frailty, which has been defined in recent studies, 36 37 we will use estimates from published data to model this unmeasured (or inadequately measured) confounder in a sensitivity analysis. We will assume that prevalence of frailty varies from 5% to 20% in those aged 65 years or older, 36 37 that frail individuals are two to four times more likely to be hospitalised or die 5 and assume that frail individuals have a 50% lower probability of being vaccinated. 38 
Sample size
In our related VIPER study, 12 the VE estimates were of the order 50% or greater, depending upon the end point, even though the follow-up time was limited to 90 days after vaccination. The power calculations are based upon a comparison of rates, assuming a Poisson distribution, for consultations, hospitalisations and deaths. Baseline rates are derived from previous studies for hospitalisations and consultations in VIPER 12 and surveillance data from the Pandemic Influenza Primary Care Reporting system. 39 For mortality, rates are derived from statistics published by National Records Scotland. 40 For the virological response, the power is derived from the comparison of two proportions and baseline swab positivity derived from Hardelid et al. 41 In all cases, an adjustment for the effective population size is made using design effects, estimated from Pandemic Influenza Primary Care Reporting and the VIPER study, ranging from 1.07 to 1.15 associated with the clustering of patients within general practices. Power is calculated for a single year and also for the whole 9-year period, assuming that the vaccine effect is similar in all seasons. For hospitalisations, deaths and virology we anticipate using a 6-month comparison period within each season, while for general practice consultations, a 1-month period is used in the power calculation, although in the analysis a longer time will be used. Power calculations are summarised in table 1. Hospitalisations due to respiratory disease Hospitalisations for influenza are rare at 50/100 000/ year and for a single year we will have a power of 83% to detect a 70% vaccine effect. Combining the 9 years of data gives a power of 80% for a 30% vaccine effect. By aggregating both influenza and pneumonia hospital admission, the underlying rate increases over fivefold, and the power to detect a vaccine effect of 40% in a single year is 86% and 85% for a 15% vaccine effect over 9 years (table 1) .
Mortality
All cause
Among people over 65 years, the death rate from all causes in Scotland is 5000/100 000. Assuming that 55%e75% of the age group are vaccinated, then this study has a power in excess of 80% to detect a difference of 20% or more in the proportions of vaccinated and unvaccinated individuals dying over a period of 6 months. Assuming similar vaccine effect in each of the 9 years, the power approaches 90% to detect a 7% vaccine effect.
Respiratory deaths
Reductions in respiratory deaths will also be included as a compound outcome. These account for 15% deaths. The estimated 30% reduction in mortality between vaccinated than unvaccinated individuals is a conservative estimate based on data from previous research (eg, Nichol et al 5 found a 58% reduction in mortality between vaccinated and unvaccinated in over 65s). For the compound respiratory deaths end point, we will have at least 80% power to detect a 50% mortality reduction in a single year and over 90% power to detect a 20% vaccine effect over the 9-year period.
Primary care consultations for influenza-like illness and acute respiratory infection
Consultation rates for influenza-like illnesses and acute respiratory infections are of the order of 30/ 100 000/day and over the period of 1 month the whole cohort will have a power of 84% to detect a difference of 40% in consultation rates between the vaccinated and unvaccinated. Extending to nine seasons, the power is over 80% to detect a 15% vaccine effect. Extending the follow-up time each season will increase the power. Vaccine uptake is assumed to be at 15% of the whole population.
Laboratory-confirmed influenza infection
During the period of influenza activity, swab positivity for influenza is around 30%. If there are 800 swabs collected per year and there is a 15% vaccine uptake, then a vaccine effect of 45% can be detected in a single season with a power of 87% and a vaccine effect of 15% detected over 9 years with a power of 83%. With fewer swabs taken, the power is smaller though even if only 400 swabs are taken per year, a vaccine effect of 20% can be detected with just under 80% power.
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